Daewoong's Subsidiary Daewoong Pharmaceutical Gets Mexico Approval for Diabetes Drug Envlo 0.3mg… Expected to Boost Overseas Sales via Latin American Market Entry
Daewoong's subsidiary Daewoong Pharmaceutical received marketing approval from Mexico's COFEPRIS for Envlo (Enavogliflozin) 0.3mg, a domestic new drug (No. 36) for type 2 diabetes with SGLT2 inhibition mechanism.
This approval enables Daewoong to enter the Latin American market, starting with Mexico, expecting to boost overseas revenue. Plans include tailored marketing strategies and product launch.
Application was in April 2024, approval in May 2026. This disclosure is based on confirmation date (2026-05-26).
[AI Comprehensive Analysis]This Mexico approval is a milestone for Daewoong's global expansion, but actual revenue impact depends on local sales performance; thus short-term stock effect may be limited. Positively seen for medium-to-long-term overseas revenue diversification.
KOSPI Filing Information
Filing: Major Management Matters Related To Investment Decision (Major Management Matters Of Subsidiary) (Approval Of Envlo 0.3mg In Mexico)